文献速递自身炎症与 IgG4 相关病其他结缔组织病

持续性IL-18驱动Still病和巨噬细胞活化综合征中CD38+HLA-DR+CD8+T细胞扩增

Persistent Interleukin-18 Fuels Expansion of CD38+HLA-DR+CD8+ T Cells in Still Disease and Macrophage Activation Syndrome.
PubMed 文献 · Arthritis Rheumatol · 2026-09-01

该研究纵向分析Still病(SD)起病时、临床不活动期及巨噬细胞活化综合征(MAS)发生前后的CD38+HLA-DR+CD8+T细胞,发现该细胞群从SD起病即扩增并在MAS时达峰值,且与血清IL-18水平相关;体外持续IL-18刺激可诱导其扩增并重现关键表型。

要点

  • CD38+HLA-DR+CD8+T细胞在SD起病时即扩增,MAS时达峰值。
  • 该细胞频率与全身炎症标志物、T细胞活化标志物及血清IL-18水平相关。
  • 体外持续IL-18刺激可诱导该细胞群持久扩增并重现离体表型特征。

核心结论

  • CD38+HLA-DR+CD8+T细胞在SD早期即可检测到,持续性IL-18暴露促进其扩增,该细胞群是SD与MAS之间的潜在机制联系及候选治疗靶点。

研究设计与样本

  • 纵向分析SD起病时(未治疗;n=19)、临床不活动期(n=15)及MAS发生前或发生时(n=12)的CD38+HLA-DR+CD8+T细胞,采用光谱流式细胞术和bulk RNA测序,并评估与临床和实验室参数的相关性。
  • 对健康供者(HD)外周血单个核细胞和CD8+淋巴细胞进行体外细胞因子刺激以探索驱动该细胞分化的机制。

主要发现

  • CD38+HLA-DR+CD8+T细胞从SD起病即扩增,在MAS时达峰值(中位数分别为4.61%和31.7%,HD为0.87%)。
  • 该细胞转录组显示活化、细胞毒性和增殖程序富集,并在蛋白水平得到确认。
  • 该细胞频率与全身炎症标志物、T细胞活化标志物及血清IL-18水平相关。
  • 体外持续IL-18刺激诱导CD38+HLA-DR+CD8+细胞强劲且持久扩增,重现离体关键表型特征。

临床怎么用

  • CD38+HLA-DR+CD8+T细胞可作为SD疾病活动及MAS风险的潜在监测指标。
  • 持续性IL-18暴露促进该细胞扩增,提示靶向IL-18或该T细胞亚群可能成为SD/MAS的治疗策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Still disease (SD) is an autoinflammatory disorder characterized by remarkably high interleukin-18 (IL-18) levels. Increasing evidence suggests that adaptive immunity also contributes to its pathogenesis, particularly in refractory courses. Macrophage activation syndrome (MAS), one of SD's most severe complications, is associated with further IL-18 elevation and expansion of CD38+HLA-DR+CD8+ T cells. However, whether and when this population emerges during SD remains unknown. We therefore examined CD38+HLA-DR+CD8+ T cells across disease stages. METHODS: CD38+HLA-DR+CD8+ T cells were analyzed longitudinally: at SD onset (therapy-naive; n = 19), during clinically inactive disease (n = 15), and before or at MAS occurrence (n = 12). Spectral flow cytometry and bulk RNA sequencing were performed. Correlations with clinical and laboratory parameters were assessed. In vitro cytokine stimulations of healthy donor (HD)-derived peripheral blood mononuclear cells and CD8+ lymphocytes were performed to explore mechanisms driving differentiation of these cells. RESULTS: CD38+HLA-DR+CD8+ T cells were expanded from SD onset and peaked in MAS (median: 4.61% and 31.7%, respectively, versus 0.87% in HDs). Transcriptomic profiling of these cells revealed enrichment of activation, cytotoxicity, and proliferation programs, which were confirmed at the protein level. Frequencies correlated with markers of systemic inflammation, T cell activation, and serum IL-18 levels. Sustained IL-18 stimulation in vitro induced robust and persistent expansion of CD38+HLA-DR+CD8+ cells, recapitulating key ex vivo phenotypic features. CONCLUSION: CD38+HLA-DR+CD8+ cells, previously primarily associated with MAS, are detectable early in SD. Persistent IL-18 exposure promotes their expansion. These findings identify CD38+HLA-DR+CD8+ T cells as a potential mechanistic link between SD and MAS and highlight this subset as a candidate therapeutic target.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Rogani G, Erkens RGA, Bodelón A, et al. Persistent Interleukin-18 Fuels Expansion of CD38+HLA-DR+CD8+ T Cells in Still Disease and Macrophage Activation Syndrome. Arthritis Rheumatol. 2026. PMID: 42678170. doi:10.1002/art.70319

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。